HC Wainwright has initiated coverage on 4D Molecular Therapeutics Inc FDMT with a price target of $36 and a Buy rating.
The analyst lists the following reasons for being bullish on the stock.
The analyst believes R100 intravitreal vector delivery in wet age-related macular degeneration patients could define a paradigm shift in available therapies, specifically in the context of SOC repeat intravitreal injections of anti-VEGF therapy.
With the vector pipeline spanning ophthalmology, cardiology, pulmonology, and vector transport by multiple delivery methods, HC Wainwright believes there are multiple opportunities for optimized vector targeting.
The analyst highlights supportive interim results from the ongoing Phase 1/2 trial.
Recently, the company announced interim clinical data from cohort 1 of the Phase 1/2 trial of intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD).
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
